Well-tolerated direct-acting antiviral medications (DAAs) can achieve sustained virological response (SVR) in at least 95% of all patient populations infected with the hepatitis C virus. But what does “curing” HCV mean for both liver and nonliver HCV-related complications?
To what degree is long-term HCV-related liver damage ameliorated by SVR? How can cirrhosis, liver failure, and HCC be best avoided (or managed) in formerly infected patients? If, as the evidence strongly suggests, conditions like insulin resistance, type 2 diabetes, cardiovascular disease, and cryoglobulinemia are directly related to active HCV infection, what are the effects of achieving SVR?
In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto analyze the evidence on how HCV cure can impact the outcomes of hepatic and nonhepatic HCV complications.
Associate Professor of Medicine
University of Toronto
University of Toronto, Toronto Centre for Liver Disease
Erasmus University Rotterdam
Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
The Johns Hopkins Hospital
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: April 19, 2019
Expiration date: April 18, 2021